{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-050724","form_type":"8-K","ticker":"AVIR","cik":"0001593899","company_name":"Atea Pharmaceuticals, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.745384+00:00","generated_at":"2026-06-05T08:52:21.871832+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Atea reports $136M FY2023 net loss; HCV Phase 2 confirms 98% SVR4; COVID-19 Phase 3 enrollment >1,400","bullets":["Q4 net loss $39.2M ($0.47 diluted EPS) vs $34.4M loss in Q4 2022; FY net loss $136.0M ($1.63) vs $115.9M.","Cash & marketable securities $578.1M at Dec 31, 2023, down from $646.7M at Dec 31, 2022.","HCV Phase 2 lead-in final results: 98% SVR4 (58/59 patients); enrollment reinitiated for up to 220 patients, including cirrhotics.","COVID-19 Phase 3 SUNRISE-3: >1,400 patients enrolled in monotherapy cohort; interim analyses expected March 2024 and Q2 2024.","Topline results for SUNRISE-3 and HCV Phase 2 SVR12 both anticipated in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-050724","json":"https://secwatch.observer/filing/0001193125-24-050724.json","markdown":"https://secwatch.observer/filing/0001193125-24-050724.md","text":"https://secwatch.observer/filing/0001193125-24-050724.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/0001193125-24-050724-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/d791287d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:52:21.871832+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b5bbfe01cc397b3271913ee59e4777d8c5afb2ae","claim":"Atea Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1593899/000119312524050724/0001193125-24-050724-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}